Relationship between clinicopathological parameters of colon cancer cases and expression of EDA.

<p>Relationship between clinicopathological parameters of colon cancer cases and expression of EDA.</p

Orthotopic xenografts derived from transfected cells and control cells.

<p>Seven to 8 wk old male BALB/c nude mice were orthotopically implanted with 6 groups of tumor xenografts. (A) Representative images of xenografts. Orthotopic images of xenograft tumors derived from 6 groups of transfected cells and control cells. Scale bar = 5 mm. (B) Expression of LYVE-1 was used to count LMVD in xenografts by immunohistochemical staining. The distribution of lymph vessels was stained brown under the light microscope. Scale bar  = 50 µm. (C) Quantification of lymph microvessel density (LMVD) is shown. The results shown are the average of three experiments. ** p < 0.01, as compared with control group. The values are displayed as the mean ± SEM.</p

Immunohistochemical staining for EDA and VEGF-C in human colorectal carcinoma.

<p>Representative images of EDA expression in human colorectal carcinoma tissues (B) and in normal colorectal mucosae (A) are shown. Representative images of VEGF-C expression in colorectal carcinoma tissues (E) and in normal mucosae (D) are shown. Inset shows higher magnification of EDA(C) and VEGF-C (F) staining (brown), distinct from the colorectal benign mucosa. (G) Linear regression of EDA and VEGF-C of 52 human colorectal cancer samples was performed. (H) Representative images of EDA expression in tissue microarrays containing tumor samples from 115 CRC patients are shown. The bottom panel shows higher magnification of EDA staining. The slides were counterstained with hematoxylin. Scale bar = 50 µm.</p

Activation of PI3K/Akt signaling pathway in transfected cells and control cells.

<p>(A) p-Akt and Akt proteins of SW620 group and SW480 group were performed by western blotting analysis. (B) Quantitative analysis shows the ratio of p-Akt/GAPDH. The error bars are standard deviations of three independent experimental results. * <i>p</i> < 0.05 and ** <i>p</i> < 0.01 are considered statistically significant and highly significant, respectively. (C) VEGF-C, p-Akt and Akt proteins of EDA-overexpressed SW620 cells were performed by western blotting when the EDA-overexpressed cells were preincubated in medium containing 0–20 µM LY294002 for 24 h. Wild type SW620 was set up as the control group. The results shown are the average of three experiments.</p

Expression of cellular and secreted VEGF-C protein in transfected cells and control cells.

<p>(A) shRNA-EDA SW480, mock SW480, pGC-FU-EDA SW620 and mock SW620 were confirmed by fluorescent microscopy. (B) Expression of EDA and VEGF-C protein was determined by western blotting. GAPDH was a loading control. VEGF-C protein concentration in transfected SW480 group(C) and transfected SW620 group (D) was detected by ELISA. This experiment was repeated in duplicate more than three times. The error bars are the means ± SEM. and ** <i>p</i> < 0.01 is considered as statistically significant. Scale bar  = 50 µm.</p

Meta-analysis for the association between Fas -1377 G/A polymorphism and cancer risk by fixed-effects model (recessive model; stratified by ethnicity).

<p>Meta-analysis for the association between Fas -1377 G/A polymorphism and cancer risk by fixed-effects model (recessive model; stratified by ethnicity).</p

Forest plot of cancer susceptibility associated with <i>PSCA</i> rs2294008 polymorphism under TT vs CC stratified according to cancer type.

<p>For each study, the estimates of OR and its 95% CI were plotted with a box and a horizontal line. The symbol filled diamond indicates pooled OR and its 95% CI. Random effects meta-analysis shows a significant association.</p

Main results of the pooled data in the meta-analysis.

<p>AML: acute myeloid leukemia; P_h: p-value of heterogeneity test; CI: confidence interval; OR: odds ratio;</p><p>^*meta-analysis results after removing the studies deviating from Hardy-Weinberg equilibrium (HWE).</p

Funnel plots of <i>PSCA</i> rs2294008 polymorphism and cancer risk (Begg: <i>P</i> = 0.442; Egger: <i>P</i> = 0.316; model: TT + CT vs CC).

<p>Each point represents an individual study for the indicated association.</p

Main characteristics of the 27 eligible studies.

<p>PCR: polymerase chain reaction; PCR-RFLP: PCR-restriction fragment length polymorphism; TaqMan: TaqManSNP; AML: acute myeloid leukemia; SCCHN: squamous cell carcinoma of the head and neck; HWE: Hardy-Weinberg equilibrium.</p